Founders Financial Securities LLC Purchases New Holdings in Johnson & Johnson (JNJ)

Founders Financial Securities LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 5,620 shares of the company’s stock, valued at approximately $743,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. State Street Corp boosted its holdings in Johnson & Johnson by 4.3% during the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after acquiring an additional 6,656,371 shares during the period. Harbour Capital Advisors LLC boosted its holdings in Johnson & Johnson by 13,327.8% during the 2nd quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock valued at $18,909,000 after acquiring an additional 2,482,843 shares during the period. Korea Investment CORP boosted its holdings in Johnson & Johnson by 38.9% during the 1st quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock valued at $265,296,000 after acquiring an additional 596,134 shares during the period. Bank of Nova Scotia boosted its holdings in Johnson & Johnson by 94.5% during the 1st quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock valued at $145,914,000 after acquiring an additional 569,313 shares during the period. Finally, Oppenheimer Asset Management Inc. purchased a new position in Johnson & Johnson during the 1st quarter valued at about $65,598,000. Institutional investors and hedge funds own 65.93% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Founders Financial Securities LLC Purchases New Holdings in Johnson & Johnson (JNJ)” was posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.thestockobserver.com/2017/11/15/founders-financial-securities-llc-purchases-new-holdings-in-johnson-johnson-jnj.html.

A number of equities analysts recently commented on the company. J P Morgan Chase & Co raised their target price on Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a report on Wednesday, August 16th. Jefferies Group LLC set a $145.00 target price on Johnson & Johnson and gave the company a “hold” rating in a report on Tuesday, August 15th. UBS AG restated a “buy” rating and set a $148.00 target price (up from $136.00) on shares of Johnson & Johnson in a report on Wednesday, July 19th. BTIG Research cut Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 target price for the company. in a report on Friday, July 21st. Finally, Vetr cut Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price for the company. in a report on Monday, September 18th. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $143.70.

Shares of Johnson & Johnson (NYSE:JNJ) opened at $139.49 on Wednesday. The firm has a market capitalization of $375,468.03, a PE ratio of 19.57, a PEG ratio of 2.84 and a beta of 0.82. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $144.35. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.68 earnings per share. research analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.41%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is 58.33%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply